Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin
Author:
Open Access
- 6 December 2019
- journal article
- conference paper
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2019 (1) , 175-181
Abstract
Patients with cancer have an increased risk of thromboembolism, which is the second leading cause of death in these patients. Several mechanisms of the prothrombotic state in these patients have been proposed. Among them are a platelet activation receptor, C-type lectin-like receptor 2 (CLEC-2), and its endogenous ligand podoplanin, which are the focus of this review. CLEC-2 is almost specifically expressed in platelets/megakaryocytes in humans. A membrane protein, podoplanin is expressed in certain types of cancer cells, including squamous cell carcinoma, brain tumor, and osteosarcoma, in addition to several normal tissues, including kidney podocytes and lymphatic endothelial cells but not vascular endothelial cells. In the bloodstream, podoplanin induces platelet activation by binding to CLEC-2 and facilitates hematogenous cancer metastasis and cancer-associated thrombosis. In an experimental lung metastasis model, the pharmacological depletion of CLEC-2 from platelets in mice resulted in a marked reduction of lung metastasis of podoplanin-expressing B16F10 cells. Control mice with B16F10 orthotopically inoculated in the back skin showed massive thrombus formation in the lungs, but the cancer-associated thrombus formation in CLEC-2–depleted mice was significantly inhibited, suggesting that CLEC-2–podoplanin interaction stimulates cancer-associated thrombosis. Thromboinflammation induced ectopic podoplanin expression in vascular endothelial cells or macrophages, which may also contribute to cancer-associated thrombosis. CLEC-2 depletion in cancer-bearing mice resulted in not only reduced cancer-associated thrombosis but also reduced levels of plasma inflammatory cytokines, anemia, and sarcopenia, suggesting that cancer-associated thrombosis may cause thromboinflammation and cancer cachexia. Blocking CLEC-2–podoplanin interaction may be a novel therapeutic strategy in patients with podoplanin-expressing cancer.Keywords
This publication has 50 references indexed in Scilit:
- Platelet ITAM signaling is critical for vascular integrity in inflammationJournal of Clinical Investigation, 2013
- Platelet Activation Receptor CLEC-2 Regulates Blood/Lymphatic Vessel Separation by Inhibiting Proliferation, Migration, and Tube Formation of Lymphatic Endothelial CellsJournal of Biological Chemistry, 2012
- Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylationNeuro-Oncology, 2012
- Podoplanin: emerging functions in development, the immune system, and cancerFrontiers in Immunology, 2012
- Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndromeBlood, 2011
- Podoplanin Is Regulated by AP-1 and Promotes Platelet Aggregation and Cell Migration in OsteosarcomaThe American Journal of Pathology, 2011
- Essential in Vivo Roles of the C-type Lectin Receptor CLEC-2Journal of Biological Chemistry, 2010
- Podoplanin Is a Novel Fos Target Gene in Skin CarcinogenesisCancer Research, 2008
- Molecular analysis of the pathophysiological binding of the platelet aggregation‐inducing factor podoplanin to the C‐type lectin‐like receptor CLEC‐2Cancer Science, 2007
- A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2Blood, 2006